Custom service

Anti-idiotype Antibody Production

Reagents that recognise the paratope, not the antigen.

Timeline: 12–16 weeks — to validated anti-IDTypes: Ab2α / Ab2β — framework vs paratope-specificFormats: Fab, F(ab')2, IgG — species-matched options

An anti-idiotype antibody binds the variable region of another antibody. Depending on where it lands, it either recognises framework determinants shared across a family — the α type — or the antigen-combining site itself, the β type. The second is the one that matters commercially: it can act as a surrogate antigen, a pharmacokinetic capture reagent, or a positive control for anti-drug antibody assays.

Generating one is not a standard immunisation. The immunogen is the target antibody itself, or its Fab/F(ab')2 fragment to focus the response on the variable region and suppress constant-domain epitopes. Because the injected antibody is itself immunogenic in a foreign species, the campaign is run in mice or rabbits, and each fusion is screened against the intact target, against its Fab, and against an isotype-matched irrelevant antibody. Only wells that bind the Fab and not the isotype control are carried forward.

Specificity is the whole product. An anti-idiotype that also binds the framework of every human IgG1 is not an anti-idiotype, it is an anti-human IgG. Screening therefore includes panels of isotype-matched antibodies and, where available, the same antibody after antigen saturation — a true paratope-specific clone loses binding when the antigen occupies the site.

Service Highlights

Where it fits

Anti-idiotypes are essential in three places: pharmacokinetic assays that must measure free drug without interference from the target, immunogenicity assays that need a positive control with a defined paratope, and vaccine work where a β-type anti-idiotype serves as a surrogate for a polysaccharide or a small hapten that cannot be coated on a plate.

The approach is less useful when the target antibody is polyclonal or when its paratope is unknown and unstable. It is also a poor economic choice for a single assay run — the campaign costs more than the assay will ever return.

Documentation and QC

Each clone is delivered with a binding matrix against the target, its Fab, an isotype control and an unrelated antibody, plus competition data establishing α or β behaviour. Affinity to the Fab is measured by BLI, and any cross-reactivity to pooled human or mouse IgG is quantified and reported.

Frequently asked questions

What is the difference between Ab2α and Ab2β?

α-type anti-idiotypes bind framework determinants outside the combining site; β-type bind within or adjacent to the paratope and can mimic the antigen. Only β-type antibodies block antigen binding, which is why the classification is tested rather than assumed.

Can you make an anti-idiotype against a humanised antibody?

Yes, and the humanised framework reduces the number of foreign epitopes, which tends to focus the response on the CDRs. A Fab immunogen further improves the ratio of paratope-specific clones.

How specific is specific enough?

For PK assays we aim for no detectable binding to pooled IgG at 10 µg/mL and a signal-to-noise above 20 against the target Fab. The acceptance criteria are agreed before screening starts.

Send the target antibody and describe the assay it will sit in. Paratope specificity is a screening question, and we will tell you whether your target is likely to yield a β-type clone before the campaign begins.

Service Highlights

  • Fab immunogen. Papain-derived Fab or F(ab')2 as immunogen, with constant-domain epitopes masked by tolerisation or removed by screening.
  • Competitive epitope screening. Clones are tested with and without saturating antigen; paratope-specific binders drop out, framework binders do not.
  • Subtype classification. Α versus β behaviour is documented by competition ELISA and by BLI epitope binning against the antigen.
  • Species and isotype matching. Anti-mouse, anti-human, anti-rabbit and anti-VHH reagents in the detection species you need.
  • Surrogate antigen use. Β-type anti-idiotypes are validated for the ability to block antigen binding, which is the property that makes them useful as assay calibrators.
  • Conjugation-ready. Supplied unlabelled or pre-conjugated to HRP, biotin or magnetic beads for immediate assay use.

How the work runs

  1. Target antibody qualification

    Purity, aggregation and antigen-binding activity of the immunogen are confirmed. Aggregated IgG produces a response dominated by constant-region epitopes.

  2. Fragment preparation

    Fab or F(ab')2 is generated enzymatically and purified by SEC, with intact IgG removal confirmed by SDS-PAGE.

  3. Immunisation and tolerance

    Mice are immunised with the fragment; where the target is a mouse antibody, a rat or rabbit host is used to avoid self-tolerance.

  4. Differential screening

    Supernatants are screened against Fab, intact target, isotype control and an unrelated Fab. Ratio-based selection identifies paratope-directed clones.

  5. Competition validation

    Antigen competition ELISA and BLI binning establish whether the clone is α or β type, and whether it blocks antigen binding.

  6. Subcloning and production

    Two rounds of limiting dilution, isotyping, then scale-up to the required milligram quantity with conjugation if requested.

Specifications & timeline

Timeline
12–16 weeks — to validated anti-ID
Types
Ab2α / Ab2β — framework vs paratope-specific
Formats
Fab, F(ab')2, IgG — species-matched options
Timeline
12–16 weeks including screening and validation
Immunogen
Intact IgG, Fab or F(ab')2; 200–500 µg per campaign
Screening panel
Target Fab, intact target, isotype control, unrelated Fab, antigen-saturated target
Host species
Mouse, rat, rabbit; matched to the species of the target antibody
Deliverables
2–4 cloned anti-idiotypes, α/β classification, competition data, 1–10 mg purified IgG
Formats
IgG, Fab, F(ab')2, biotin or HRP conjugate

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.